Sort by
Refine Your Search
-
Martin Australia invite applications for a project under this program, advancing robotic perception systems through monitoring of their machine learning models. Run-Time Monitoring of Machine Learning
-
This PhD research scholarship (Learning Lessons from Drug Resistance to Tackle Herbicide Resistance) is funded by the Australian Research Council to support a full-time PhD student to undertake
-
. Please submit the following documents by 5.00pm Tuesday 20 January 2026 to: Healthy Development Adelaide, Anne Jurisevic at anne.jurisevic@adelaide.edu.au Completed HDA Application (doc format - in font
-
group of PhD researchers who will tackle the most pressing questions in Machine Learning while ensuring AI serves humanity responsibly. You'll work within one of our specialised research themes, each
-
excellence by providing a highly collaborative environment that benefits the research of all its scientists, whether at the graduate, post-doctoral or group leader level. A key initiative of the associate
-
countries to customers such as global government, business and corporate, NGOs, aid and humanitarian organisations, security and military groups, public safety, emergency response, broadcast and consumer
-
where? Eligibility: Applicants must be accepted for admission into a Doctor of Philosophy at the University of Adelaide and enrolling in one of the 5 approved PhD projects . Applicants must be awarded a
-
Statistics for the Australian Grains Industry 3 (SAGI3). Investment. The University of Adelaide, in collaboration with Curtin University and The University of Queensland, is leveraging machine learning, data
-
Division) equivalent (approximately 75 Weighted Average Mark) Commence study in 2026, not before. Current postgraduate students are not eligible. MD and Juris Doctor programs or any Masters by Coursework
-
into fundamental molecular events. At the same time, access to translational pipelines will enable the candidate to apply their learnings in a meaningful way, revealing novel therapeutic targets critical for cancer